KAS
CORT icon

Kestra Advisory Services’s Corcept Therapeutics CORT Stock Holding History

Kestra Advisory Services’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,194
Closed -$181K – 3364
2025
Q4 		$181K Sell
5,194
-1,653
-24% -$130K ﹤0.01% 2982
2025
Q3 		$569K Sell
6,847
-346
-5% -$25K ﹤0.01% 1964
2025
Q2 		$528K Buy
7,193
+286
+4% +$20.7K ﹤0.01% 1931
2025
Q1 		$789K Sell
6,907
-2,618
-27% -$159K ﹤0.01% 1537
2024
Q4 		$480K Buy
9,525
+1,039
+12% +$54.4K ﹤0.01% 1899
2024
Q3 		$393K Sell
8,486
-15,860
-65% -$564K ﹤0.01% 1920
2024
Q2 		$791K Sell
24,346
-6,488
-21% -$178K ﹤0.01% 1474
2024
Q1 		$777K Buy
+30,834
New +$728K 0.01% 1400
2021
Q1 		– Sell
-10,072
Closed -$264K – 1887
2020
Q4 		$264K Buy
+10,072
New +$212K ﹤0.01% 1533

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Kestra Advisory Services's CORT Position: Q1 2026 in Review

Kestra Advisory Services sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 5,194 shares — an estimated $181K sold.

Kestra Advisory Services first reported a position in CORT in Q4 2020 and held it in 9 quarters. The position peaked at $791K in Q2 2024. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Kestra Advisory Services reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 5,194 Corcept Therapeutics shares in Q1 2026, an estimated $181K.
  • Kestra Advisory Services first reported a position in Corcept Therapeutics in Q4 2020 and held it in 9 quarters.
  • Kestra Advisory Services's Corcept Therapeutics position peaked at $791K in Q2 2024.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.